CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 6700-6707

  Chen, Huilong ^a   Xu, Xiangqin ^a   Teng, Jieming ^a   Cheng, Sheng ^a   Bunjhoo, Hansvin ^a   Cao, Yong ^a   Liu, Jin ^a   Xie, Jungang ^a   Wang, Congyi ^a   Xu, Yongjian ^a   Xiong, Weining ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Asthma; CXCL12; CXCR4; MMP 9

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, HUMAN; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, HUMAN; CXCR4 PROTEIN, MOUSE; GELATINASE B; HETEROCYCLIC COMPOUND; INTERLEUKIN 13; MAPK1 PROTEIN, HUMAN; MAPK1 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, MOUSE; OVALBUMIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; ASTHMA; BAGG ALBINO MOUSE; BRONCHUS; CELL LINE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; PNEUMONIA; SIGNAL TRANSDUCTION; TIME FACTOR;

ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHI; CELL LINE; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; INTERLEUKIN-13; MATRIX METALLOPROTEINASE 9; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVALBUMIN; PNEUMONIA; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84938633467     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001; 2: 515-22.
2. Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, Morita Y, Hirai K. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol 2000; 164: 5935-43.
3. Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol 2000; 165: 499-508.
4. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160: 1353-60.
5. Negrete-García MC, Velazquez JR, Popoca-Coyotl A, Montes-Vizuet AR, Juárez-Carvajal E, Teran LM. Chemokine (C-X-C motif) ligand 12/stromal cell-derived factor-1 is associated with leukocyte recruitment in asthma. Chest 2010; 138: 100-6.
6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
7. Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med 2003; 9: 28-33.
8. Cataldo DD, Tournoy KG, Vermaelen K, Munaut C, Foidart JM, Louis R, Noël A, Pauwels RA. Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol 2002; 161: 491-8.
9. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, Mautino G, D'accardi P,.Bousquet J, Bonsignore G. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-50.
10. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997; 17: 583-91.
11. Bossé M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159: 596-602.
12. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, Moore JP. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998; 4: 72-7.
13. Schols D, Esté JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997; 35: 147-56.
14. Cheng S, Chen H, Wang A, Bunjhoo H, Cao Y, Xie J, Xu Y, Xiong W. Exclusion of IL-21 in the pathogenesis of OVA-induced asthma in mice. Int J Clin Exp Med 2014; 7; 3202-3208.
15. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130: 829-42; quiz 843-4.
16. Mitchell J, Dimov V, Townley RG. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr Opin Investig Drugs 2010; 11: 527-34.
17. Martinez FD, Vercelli D. Asthma. Lancet 2013; 382: 1360-72.
18. Ueno-Iio T, Shibakura M, Iio K, Tanimoto Y, Kanehiro A, Tanimoto M, Kataoka M. Effect of fudosteine, a cysteine derivative, on airway hyperresponsiveness, inflammation, and remodeling in a murine model of asthma. Life Sci 2013; 92: 1015-23.
19. Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD, Wallace JL, Befus AD, Moqbel R. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol 2000; 106: 537-45.
20. Lee KS, Min KH, Kim SR, Park SJ, Park HS, Jin GY, Lee YC. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J Respir Crit Care Med 2006; 174: 161-70.
21. Liu CP, Hsieh CH, Wu BN, Yeh JL, Dai ZK, Chai CY, Chen IJ. Inhaled KMUP-1 Prevents Allergic Pulmonary Vascular Inflammation and Remodeling via NO and Suppressed MMP-9 and ICAM-1/VCAM-1. Inflamm Allergy Drug Targets 2012; 11: 251-61.
22. Luan B, Huang XJ, Qiao JY. Expression of stromal cell derived factor-1 and CXC chemokine receptor 4 and the effects of budesonide on their expression in mice with asthma. Zhongguo Dang Dai Er Ke Za Zhi 2010; 12: 215-8.
23. Chiu PR, Lee WT, Chu YT, Lee MS, Jong YJ, Hung CH. Effect of the Chinese herb extract osthol on IL-4-induced eotaxin expression in BEAS-2B cells. Pediatr Neonatol 2008; 49: 135-40.
24. Ip WK, Wong CK, Lam CW. Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clin Exp Immunol 2006; 145: 162-72.
25. Laan M, Lötvall J, Chung KF, Lindén A. IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 2001; 133: 200-6.
26. Kumar A, Lnu S, Malya R, Barron D, Moore J, Corry DB, Boriek AM. Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma. FASEB J 2003; 17: 1800-11.
27. Lee EJ, Lee SJ, Kim S, Cho SC, Choi YH, Kim WJ, Moon SK. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal 2013; 25: 2025-38.
28. Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim JH, Choi YH, Kim WJ, Moon SK. Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-kappaB) activation by inducing the up-regulation of p21 (WAF1) protein expression. J Biol Chem 2013; 288: 5539-52.
29. Ma L, Lan F, Zheng Z, Xie F, Wang L, Liu W, Han J, Zheng F, Xie Y, Huang Q. Epidermal growth factor (EGF) and interleukin (IL)-1beta synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer 2012; 11: 79.